The comparison of the efficacy of four different therapeutic regimens against Hlicobacter pylori infection in End Stage Renal Disease patients.

Comparison of the effect of Helicobacter Pylori eradication regimens in patients with end stage renal disease

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015081123591N1

Enrollment

120

Registered

2015-09-01

Start date

2013-03-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori infection. Helicobacter pylori [H.pylori] as the cause of diseases classified to other chapters

Interventions

Intervention 1: Intervention group 1: RCA regimen ( capsule Clarythromycin 250 mg every 12 hours, capsule Amoxicillin 500 mg every 12 hours, tablet Rabeprazole 20 mg every 12 hours). Intervention 2: I

capsule Amoxicillin 500 mg every 12 hours and second week

capsule Clarithromycin 250 mg every 12 hours,tablet Metronidazole 500 mg every 12 hours). Intervention 4: Intervention group 2: RCM regimen (capsule Clarythromycin 250 mg every 12 hours, tablet Metron

Treatment - Drugs

Intervention group 1: RCA regimen ( capsule Clarythromycin 250 mg every 12 hours, capsule Amoxicillin 500 mg every 12 hours, tablet Rabeprazole 20 mg every 12 hours)

Intervention group 3: RCAM regimen (capsule Clarythromycin 250 mg every 12 hours, capsule Amoxicillin 250 mg every 12 hours, tablet Rabeprazole 20 mg every 12 hours, tablet Metronidazole 500 mg every

Intervention group 4: sequential regimen (tablet Rabeprazole 20 mg every 12 hours, first week

capsule Clarithromycin 250 mg every 12 hours,tablet Metronidazole 500 mg every 12 hours)

Intervention group 2: RCM regimen (capsule Clarythromycin 250 mg every 12 hours, tablet Metronidazole 500 mg every 12 hours, tablet Rabeprazole 20 mg every 12 hours)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: All ESRD patients with confirmed H.pylori infection using Endoscopic gasterodeodenoscopy with complete consciousness of patient about research. Exclusion criteria: Pregnancy, liver failure, patient with active cancer, recent using of Proton pomp inhibitors, Non steroidal anti inflammatory drugs, bismuth and antibiotics during last four weeks, history of alcohol abuse, cigarette smoking and any drug reactions.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Helicobacter pylori. Timepoint: 4 weeks after finishing of treatment course. Method of measurement: Patients swallow urea labelled with an uncommon isotope, either radioactive carbon-14 or non-radioactive carbon-13. In the subsequent 10–30 minutes, the detection of isotope-labelled carbon dioxide in exhaled breath indicates that the urea was split; this indicates that urease (the enzyme that H. pylori uses to metabolize urea) is present in the stomach, and hence that H. pylori bacteria are present.	—

Measure

Time frame

Helicobacter pylori. Timepoint: 4 weeks after finishing of treatment course. Method of measurement: Patients swallow urea labelled with an uncommon isotope, either radioactive carbon-14 or non-radioactive carbon-13. In the subsequent 10–30 minutes, the detection of isotope-labelled carbon dioxide in exhaled breath indicates that the urea was split; this indicates that urease (the enzyme that H. pylori uses to metabolize urea) is present in the stomach, and hence that H. pylori bacteria are present.

—

Secondary

Measure	Time frame
-. Timepoint: -. Method of measurement: -.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Peyman Sanjari Pirayvatlou

Golestan University of Medical Scienced

dr.p.sanjari@gmail.com+98 17 3247 0110

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026